Alerts continue on counterfeit product and unapproved salt forms
Two different problems with one outcome: an unverified substance in a syringe.
Regulators and manufacturers have continued issuing alerts about falsified branded product reaching patients through unlicensed sellers, and about unregulated peptide sold with research-use disclaimers.
Separately, FDA has distinguished semaglutide base from salt forms such as semaglutide sodium and acetate, and has linked the salt forms to safety concerns. A legitimate compounded preparation uses the base peptide.
Neither problem is detectable by inspection, which is the whole argument for the licensed channel. Ask which form your pharmacy compounds from, and ask for the certificate of analysis for your lot.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement or the clinical review behind a prescription.
Where a development moves a figure we publish, the change is recorded with its date on our methodology page rather than edited in silently.
How to verify this yourself
Regulatory claims should be checked against the agency rather than coverage of the agency. FDA publishes warning letters searchable by company name and a drug shortage database, both free and both more current than any summary.